Senti Biosciences
Latest round
- Series B
Last raised
- Jan 2021
Total raised
- $144M
Investors
- 22
About Senti Biosciences
Senti Biosciences, Inc.Founded in 2016 and headquartered in San Francisco, California, Senti Biosciences, Inc. specializes in creating innovative cell therapies. The company has undergone strategic pivots to refine its focus on Gene Circuit technology. The co-founders, Philip Lee and Tim Lu, have backgrounds in biotechnology, contributing to the company's vision.Senti Bio focuses on developing advanced cell therapies through its proprietary Gene Circuit technology, designed to create smarter medicines for patients with incurable diseases, particularly in the oncology space.S. for the treatment of acute myeloid leukemia (AML). The Gene Circuits are engineered from unique combinations of DNA sequences that reprogram cells to respond intelligently to their environment. This technology aims to enhance the precision of cancer treatments by specifically targeting cancer cells while sparing healthy cells, thereby increasing therapeutic efficacy and reducing side effects.Senti Bio's revenue structure is primarily based on collaborations and partnerships within the biopharmaceutical sector. The company engages with healthcare providers and research institutions to conduct clinical trials, which may involve upfront payments and subsequent milestone payments tied to the achievement of specific regulatory or developmental goals. Additionally, upon commercialization of products, revenue may be generated from selling its therapeutics directly to healthcare facilities or through collaborations with larger pharmaceutical companies for broader distribution.Senti Biosciences, Inc. aims to expand its product pipeline with upcoming therapies targeting additional cancer indications and expects to initiate new clinical trials in the next 18 months. The company plans to broaden its market reach, potentially entering international markets in Europe and Asia by 2024.
Who invested in Senti Biosciences
22 investors across 2 rounds
See all investors in Senti Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Senti Biosciences
Who invested in Senti Biosciences?
Senti Biosciences has 22 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Senti Biosciences raised?
Senti Biosciences has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Senti Biosciences last raise money?
Senti Biosciences's most recent round on record is a Series B, in Jan 2021.
What does Senti Biosciences do?
Senti Biosciences is a biotechnology company.
Where is Senti Biosciences headquartered?
Senti Biosciences is headquartered in San Francisco, US.
Which VCs invest in companies like Senti Biosciences?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Senti Biosciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Senti Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.